Lung Cancer

Madrid, Spain—A perioperative regimen of neoadjuvant nivolumab (Opdivo) plus chemotherapy followed by surgery and adjuvant nivolumab demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS) versus neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant placebo in patients with resectable non–small cell lung cancer. Read More ›

Risk model-based lung cancer screening strategies, which select individuals based on personal risk, are more cost-effective than current recommendations based solely on age and smoking history, according to a study led by the Cancer Intervention and Surveillance Modeling Network (CISNET) Lung Working Group, which includes researchers from The University of Texas MD Anderson Cancer Center, Houston. Read More ›

>Sotorasib (Lumakras) continues to demonstrate durable efficacy in non–small-cell lung cancer (NSCLC) with KRAS p.G12C mutation at 2-year follow-up of the phase 2 CodeBreaK 100 clinical trial. Read More ›

The phase 3 CheckMate-816 trial establishes a new standard of care for resectable non–small-cell lung cancer (NSCLC): neoadjuvant nivolumab (Opdivo) plus chemotherapy. Read More ›

Patritumab deruxtecan (HER3-DxD), an investigational antibody–drug conjugate targeting the HER3 growth factor receptor, showed promising activity in patients with locally advanced or metastatic EGFR mutation–positive non–small-cell lung cancer (NSCLC) who had received previous EGFR tyrosine kinase inhibitor (TKI) therapy, according to interim results from a phase 1 dose-escalation and dose-expansion trial. Read More ›

Dual EGFR targeting with amivantamab-vmjw (Rybrevant) plus lazertinib (Leclaza) led to durable responses in more than one-third of chemotherapy-naïve patients with EGFR-positive non–small-cell lung cancer (NSCLC) whose disease had progressed on osimertinib (Tagrisso) therapy, according to a cohort analysis of the CHRYSALIS trial. Read More ›

Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved pathologic complete response (pCR) rates versus chemotherapy alone in patients with resectable stage IB-IIIA non–small-cell lung cancer (NSCLC), according to final results from the CheckMate-816 clinical trial. Read More ›

Approximately 13% of patients with lung adenocarcinoma harbor the KRAS p.G12C mutation, which is associated with poor clinical outcomes. Read More ›

Sexual orientation and assigned sex at birth are significant determinants in the utilization of lung cancer screening, according to an analysis from the Behavioral Risk Factor Surveillance System (BRFSS) 2018, a cross-sectional, nationally representative database, that looked at screening among lesbian, gay, bisexual, transgender (LGBT) populations. Read More ›